SCHEMBL6724765

SCHEMBL6724765

c1ccc(-c2cccc(-c3ccc4c(c3)c3ccccc3n4-c3ccc(-c4nc5ccccc5nc4-c4ccccc4)cc3)c2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 5/20 0.44
KDM4E B2RXH2 5/20 0.44
ATM Q13315 2/20 0.44
KMT2A Q03164 4/20 0.42
LMNA P02545 3/20 0.42
MEN1 O00255 3/20 0.42
TDP1 Q9NUW8 2/20 0.42
GAA P10253 2/20 0.42
NPY5R Q15761 1/20 0.40
DHODH Q02127 2/20 0.40
TSPO P30536 1/20 0.40
ALDH1A1 P00352 4/20 0.39
NPSR1 Q6W5P4 1/20 0.39
THRB P10828 1/20 0.39
HSP90AA1 P07900 1/20 0.39
MAPT P10636 1/20 0.39
PTGER4 P35408 1/20 0.38
ESR1 P03372 1/20 0.38
ESR2 Q92731 1/20 0.38
AKT1 P31749 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12690686 1.00 L3MBTL1 (0.44) L3MBTL1KDM4EATMKMT2ALMNA
SCHEMBL12690906 1.00 L3MBTL1 (0.44) L3MBTL1KDM4EATMKMT2ALMNA
SCHEMBL11987935 0.99 L3MBTL1 (0.46) L3MBTL1KDM4EATMKMT2ALMNA
SCHEMBL11987938 0.97 L3MBTL1 (0.46) L3MBTL1KDM4EATMKMT2ALMNA
SCHEMBL12690904 0.97 L3MBTL1 (0.46) L3MBTL1KDM4EATMKMT2ALMNA
SCHEMBL12690742 0.97 L3MBTL1 (0.46) L3MBTL1KDM4EATMKMT2ALMNA
SCHEMBL12690741 0.97 L3MBTL1 (0.46) L3MBTL1KDM4EATMKMT2ALMNA
SCHEMBL6725348 0.97 L3MBTL1 (0.46) L3MBTL1KDM4EATMKMT2ALMNA
SCHEMBL12690642 0.97 L3MBTL1 (0.46) L3MBTL1KDM4EATMKMT2ALMNA
SCHEMBL6724694 0.97 L3MBTL1 (0.46) L3MBTL1KDM4EATMKMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8178216-B2 Quinoxaline derivative, and light-emitting element, light-emitting device, and electronic device including quinoxaline derivative SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2012-05-15 US disclosed
US-8178216-B2 Quinoxaline derivative, and light-emitting element, light-emitting device, and electronic device including quinoxaline derivative SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2012-05-15 US disclosed
US-20090072718-A1 Quinoxaline derivative, and light-emitting element, light-emitting device, and electronic device including quinoxaline derivative SEMICONDUCTOR ENERGY LABORATORY CO., LTD. 2009-03-19 US disclosed
US-20090072718-A1 Quinoxaline derivative, and light-emitting element, light-emitting device, and electronic device including quinoxaline derivative SEMICONDUCTOR ENERGY LABORATORY CO., LTD. 2009-03-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090072718-A1 Quinoxaline derivative, and light-emitting element, light-emitting device, and electronic device including quinoxaline derivative CRY1, GRK1, CRY2 L3MBTL1 826/4885KDM4E 2006/4885ATM 2120/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.